Treatment of NSCLC: Best Practices from the University of Kansas Cancer Center and Satellites : Episode 2
Determining Eligibility for Surgical Resection in NSCLC
Alykhan Nagji, MD, provides an overview of the institutional approach to determining eligibility for surgical resection, delving into the pivotal role of the multidisciplinary tumor board in the decision-making process and exploring the crucial factors that must be considered when evaluating resectability.
CN_KC_SS_Seg02
Video Player is loading.
EP: 1.Available Treatment Options for Patients With Stage-III Resectable NSCLC
Now Viewing
EP: 2.Determining Eligibility for Surgical Resection in NSCLC
EP: 3.Expert Perspectives on Perioperative Immunotherapy in Resectable Stage-III NSCLC
EP: 4.Treatment Approaches for Resectable Stage-III NSCLC in the Adjuvant Setting
EP: 5.Treatment Strategies for NSCLC Following Progression on Adjuvant Immunotherapy
EP: 6.Approaches to Treatment and Staging in Unresectable NSCLC
EP: 7.Sequential and Concurrent Chemoradiotherapy in Unresectable Stage-III NSCLC
EP: 8.Expert Insights on Adjuvant Immunotherapy in Unresectable Stage-III NSCLC
EP: 9.Managing Stage-III NSCLC with Actionable EGFR or ALK Mutations
EP: 10.The Potential Role of Combination Adjuvant Immunotherapy in NSCLC
EP: 11.Insights into Strategies Using Concurrent Immunotherapy with Chemoradiotherapy
EP: 12.Clinical Pearls for Treating NSCLC: Insights from Experts at the University of Kansas
EP: 13.Case 1: 72-Year-Old Former Smoker with Stage-IIIA NSCLC and PD-L1 of 90%
EP: 14.Case 2: 82-Year-Old Former Smoker with Poorly Differentiated Lung Adenocarcinoma and PD-L1 of 85%
EP: 15.Case 3: 70-Year-Old Former Smoker with Stage IIIB NSCLC with PD-L1 10%
EP: 16.Case 4: 71-Year-Old Diagnosed with Stage IIIA NSCLC Experiencing Pneumonitis After Chemo-IO Treatment
EP: 17.A Multidisciplinary Approach to Treating Resectable NSCLC
Recent Videos
Lorlatinib Yields No Unexpected Toxicities in ALK-Positive NSCLC
Lorlatinib Demonstrates “Fantastic” PFS Results in Advanced ALK+ NSCLC
Clinician Experiences: COCOON Regimen vs Traditional SoC AE Management
Initial Reactions to COCOON Study’s Dermatologic/Nail AE Reductions
Divarasib Combo Appears “Promising” in Pretreated KRAS G12C+ NSCLC
Looking Ahead and Key Takeaways in EGFRm NSCLC
Assessing the Adverse Effect Profile of Ami-Laz in Comparison With Other Combination Therapies in EGFRm NSCLC
COCOON: Discussion of Clinical End Points and Dose Modifications
COCOON Baseline Characteristics
Analysis of MARIPOSA & SKIPPirr Trials: Safety and Quality of Life
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
